Table of Contents Author Guidelines Submit a Manuscript
Advances in Pharmacological Sciences
Volume 2015, Article ID 521718, 11 pages
http://dx.doi.org/10.1155/2015/521718
Research Article

Comparative Effect of Lisinopril and Fosinopril in Mitigating Learning and Memory Deficit in Scopolamine-Induced Amnesic Rats

1Department of Pharmacology, Melaka Manipal Medical College, Manipal University, Manipal Campus, Manipal 576104, India
2Department of Pharmacology, Kasturba Medical College, Manipal University, Manipal 576104, India
3Department of Anatomy, Melaka Manipal Medical College, Manipal University, Manipal Campus, Manipal 576104, India

Received 10 May 2015; Revised 5 July 2015; Accepted 14 July 2015

Academic Editor: Masahiro Oike

Copyright © 2015 Debasree Deb et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Okano, T. Hirano, and E. Balaban, “Learning and memory,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 23, pp. 12403–12404, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. D. A. Drachman and J. Leavitt, “Human memory and the cholinergic system: a relationship to aging?” Archives of Neurology, vol. 30, no. 2, pp. 113–121, 1974. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Bejar, R.-H. Wang, and M. Weinstock, “Effect of rivastigmine on scopolamine-induced memory impairment in rats,” European Journal of Pharmacology, vol. 383, no. 3, pp. 231–240, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. R. W. Jones, K. A. Wesnes, and J. Kirby, “Effects of NMDA modulation in scopolamine dementia,” Annals of the New York Academy of Sciences, vol. 640, pp. 241–244, 1991. View at Google Scholar · View at Scopus
  5. U. Ebert and W. Kirch, “Scopolamine model of dementia: electroencephalogram findings and cognitive performance,” European Journal of Clinical Investigation, vol. 28, no. 11, pp. 944–949, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. W. W. Beatty, N. Butters, and D. S. Janowsky, “Patterns of memory failure after scopolamine treatment: implications for cholinergic hypotheses of dementia,” Behavioral and Neural Biology, vol. 45, no. 2, pp. 196–211, 1986. View at Publisher · View at Google Scholar · View at Scopus
  7. N. J. Brown and D. E. Vaughan, “Angiotensin-converting enzyme inhibitors,” Circulation, vol. 97, no. 14, pp. 1411–1420, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Ohrui, N. Tomita, T. Sato-Nakagawa et al., “Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression,” Neurology, vol. 63, no. 7, pp. 1324–1325, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Rozzini, B. V. Chilovi, E. Bertoletti et al., “Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment,” International Journal of Geriatric Psychiatry, vol. 21, no. 6, pp. 550–555, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Yang, O. C. Ronan, H. Liam et al., “Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia,” BMJ Open, vol. 3, no. 7, Article ID e002881, 2013. View at Publisher · View at Google Scholar
  11. G. E. Paget and J. M. Barnes, “Evaluation of drug activities,” in Pharmacometrics, D. R. Lawrence and A. L. Bacharcach, Eds., vol. 1, p. 161, Academic Press, New York, NY, USA, 1964. View at Google Scholar
  12. A. Zanotti, L. Valzelli, and G. Toffano, “Reversal of scopolamine-induced amnesia by phosphatidylserine in rats,” Psychopharmacology, vol. 90, no. 2, pp. 274–275, 1986. View at Google Scholar · View at Scopus
  13. J. Wang, X. Wang, B. Lv et al., “Effects of fructus akebiae on learning and memory impairment in a scopolamine-induced animal model of dementia,” Experimental and Therapeutic Medicine, vol. 8, no. 2, pp. 671–675, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. A. C. Sharma and S. K. Kulkarni, “Evaluation of learning and memory mechanisms employing elevated plus-maze in rats and mice,” Progress in Neuropsychopharmacology and Biological Psychiatry, vol. 16, no. 1, pp. 117–125, 1992. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Bures, O. Buresova, and J. P. Huston, Techniques and Basic Experiments for the Study of Brain and Behavior, Elsevier Science, New York, NY, USA, 2nd edition, 1983.
  16. R. Morris, “Developments of a water-maze procedure for studying spatial learning in the rat,” Journal of Neuroscience Methods, vol. 11, no. 1, pp. 47–60, 1984. View at Publisher · View at Google Scholar · View at Scopus
  17. A. V. Dhwaj and R. Singh, “Reversal effect of Asparagus racemosus wild (Liliaceae) root extract on memory deficits of mice,” International Journal of Drug Development and Research, vol. 3, no. 2, pp. 314–323, 2011. View at Google Scholar · View at Scopus
  18. R. D'Hooge and P. P. De Deyn, “Applications of the Morris water maze in the study of learning and memory,” Brain Research Reviews, vol. 36, no. 1, pp. 60–90, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Savaskan, “The role of the brain renin-angiotensin system in neurodegenerative disorders,” Current Alzheimer Research, vol. 2, no. 1, pp. 29–35, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. H. K. Hamdi and R. Castellon, “A genetic variant of ACE increases cell survival: a new paradigm for biology and disease,” Biochemical and Biophysical Research Communications, vol. 318, no. 1, pp. 187–191, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. N. R. Sims, D. M. Bowen, S. J. Allen et al., “Presynaptic cholinergic dysfunction in patients with dementia,” Journal of Neurochemistry, vol. 40, no. 2, pp. 503–509, 1983. View at Publisher · View at Google Scholar · View at Scopus
  22. G. B. Frisoni, N. C. Fox, C. R. Jack Jr., P. Scheltens, and P. M. Thompson, “The clinical use of structural MRI in Alzheimer disease,” Nature Reviews Neurology, vol. 6, no. 2, pp. 67–77, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Moria, Y. Yoneda, H. Yamashitaa, N. Hironoa, M. Ikedaa, and A. Yamadoric, “Medial temporal structures relate to memory impairment in Alzheimer's disease: an MRI volumetric study,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 63, pp. 214–221, 1997. View at Google Scholar
  24. Y. Fan, J. Hu, J. Li et al., “Effect of acidic oligosaccharide sugar chain on scopolamine-induced memory impairment in rats and its related mechanisms,” Neuroscience Letters, vol. 374, no. 3, pp. 222–226, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Hayek, J. Attias, R. Coleman et al., “The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice,” Cardiovascular Research, vol. 44, no. 3, pp. 579–587, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Hayek, J. Attias, J. Smith, J. L. Breslow, and S. Keidar, “Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice,” Journal of Cardiovascular Pharmacology, vol. 31, no. 4, pp. 540–544, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. K. M. Raizada, I. M. Phillips, and C. Sumners, “Tissue renin angiotensin systems,” in Cellular and Molecular Biology of the Renin—Angiotensin System, I. M. Phillips, E. Speakman, and B. Kimura, Eds., chapter 4, p. 97, CRC Press, New York, NY, USA, 1993. View at Google Scholar
  28. D. W. Cushman, F. L. Wang, W. C. Fung, C. M. Harvey, and J. M. DeForrest, “Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs,” American Journal of Hypertension, vol. 2, no. 4, pp. 294–306, 1989. View at Google Scholar · View at Scopus
  29. K. M. Sink, X. Leng, J. Williamson et al., “Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the cardiovascular health study,” Archives of Internal Medicine, vol. 169, no. 13, pp. 1195–1202, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. C. M. White, “Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors,” Pharmacotherapy, vol. 18, no. 3, pp. 588–599, 1998. View at Google Scholar · View at Scopus
  31. B. Singh, B. Sharma, A. S. Jaggi, and N. Singh, “Attenuating effect of lisinopril and telmisartan in intracerebroventricular streptozotocin induced experimental dementia of Alzheimer's disease type: possible involvement of PPAR-γ agonistic property,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 14, no. 2, pp. 124–136, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Zou, H. Yamaguchi, H. Akatsu et al., “Angiotensin-converting enzyme converts amyloid β-protein 1–42 (Aβ142) to Aβ140, and its inhibition enhances brain Aβ deposition,” Journal of Neuroscience, vol. 27, no. 32, pp. 8628–8635, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. J. M. Barnes, N. M. Barnes, B. Costall et al., “Angiotensin-converting enzyme inhibition, angiotensin, and cognition,” Journal of Cardiovascular Pharmacology, vol. 19, no. 6, pp. S63–S71, 1992. View at Publisher · View at Google Scholar · View at Scopus